Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya.

Slides:

Advertisements

Similar presentations

Aortic Valve Replacement With Patch Enlargement of the Aortic Annulus

Advertisements

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer Riichiroh Maruyama,

Didier Lardinois, MD, Renate Rechsteiner, MD, R

E-cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer Dage Liu, MD, Cheng-long Huang, MD, Kotaro.

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Tumor marker expression is predictive of survival in patients with esophageal cancer Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Prediction of Prognosis and Surgical Indications for Pulmonary Metastasectomy From Colorectal Cancer Toshihiko Iizasa, MD, Makoto Suzuki, MD, Shigetoshi.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: A possible association between staining patterns with neuroendocrine markers.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

Tumor-to-Tumor Metastasis: Maxillary Sinus Adenoid Cystic Carcinoma Metastasizing to Double Primary Lung Adenocarcinoma Wei-Yang Lin, MD, Wen-Hu Hsu,

Ki-67 expression and prognosis for smokers with resected stage i Non–Small cell lung cancer Yukiko Haga, MD, Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi.

Prognostic Significance of the Tumor Suppressor Gene Maspin in Non–Small Cell Lung Cancer Kyoji Hirai, MD, Kiyoshi Koizumi, MD, Shuji Haraguchi, MD,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator Yukio Watanabe, MD, Masahiko Kusumoto, MD, Akihiko Yoshida,

Iwao Takanami, MD, Ken Takeuchi, MD, Masatoshi Giga, MD

Nodular Lymphoid Hyperplasia of the Lung: A Very Rare Disease Entity

Mariano Garcı́a-Yuste, MD, José M

Surgical Treatments for Multiple Primary Adenocarcinoma of the Lung

Primary Pulmonary Lymphoma

Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors Akira Iyoda, MD, Kenzo Hiroshima, MD, Masayuki Baba,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic.

Influence of Cigarette Smoking on Survival and Tumor Invasiveness in Clinical Stage IA Lung Adenocarcinoma Ryo Maeda, MD, Junji Yoshida, MD, Genichiro.

Visceral pleural involvement in nonsmall cell lung cancer: prognostic significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu,

The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer J. Buhr,

Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma Takashi.

Flow cytometric analysis of a localized malignant mesothelioma

Long-term results after pulmonary resection of renal cell carcinoma metastases Stefan Piltz, MD, Georgios Meimarakis, MD, Matthias W Wichmann, MD, Rudolf.

Relation Between Thin-Section Computed Tomography and Clinical Findings of Mucinous Adenocarcinoma Hajime Watanabe, MD, Haruhiro Saito, MD, Tomoyuki.

The evaluation of lymph node metastasis by endobronchial ultrasound-guided transbronchial needle aspiration: Crucial for selection of surgical candidates.

Expression of vascular endothelial growth factor in thoracic sarcomas

Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity Akira Iyoda, MD, Kenzo Hiroshima, MD, Yasumitsu Moriya, MD, Teruaki.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung Marc Riquet, MD, Dominique Manac’h, MD, Françoise Le.

Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl Lewis X, and sialyl Lewis a in lung cancer Jun-ichi Ogawa, MD,

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan.

Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma Masahiko Higashiyama, MD, Ken Kodama, MD, Hideoki Yokouchi,

Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size Kyung Wook Shin, MD, Sukki Cho, MD,

Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,

Carcinoma of the esophagus: Prognostic significance of histologic type

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

The Prognostic Importance of Immunohistochemically Detected Node Metastases in Resected Esophageal Adenocarcinoma Tara A. Waterman, BA, Jeffrey A. Hagen,

Predictors of Survival After Operation Among Patients With Large Cell Neuroendocrine Carcinoma of the Lung Florian Eichhorn, MD, Hendrik Dienemann, MD,

Is there a role for pneumonectomy in pulmonary metastases?1

Lymph Node Staging by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients With Small Cell Lung Cancer Hironobu Wada, MD, Takahiro.

John E Langenfeld, MD The Annals of Thoracic Surgery

Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience Inderpal S. Sarkaria,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Kuang-Tai Kuo, MD, Kuan-Chih Chow, PhD, Yu-Chung.

Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer Bernward Passlick, MD, Boris Kubuschok, MD,

Increased Levels of Platelet-Associated Immunoglobulin G in a Patient With Pulmonary Adenocarcinoma Shohei Yoshiya, MD, Riichiroh Maruyama, MD, Dai Kitagawa,

Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker Adnan Sayar,

MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence Akira Ohgami, MD, Tohru Tsuda, MD, Toshihiro Osaki,

Pulmonary infarct cytologically mimicking adenocarcinoma of the lung

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas.

Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non–small cell carcinoma Akira Iyoda, MD, Kenzo.

Pulmonary Artery Leiomyosarcoma Expressing Epstein-Barr Virus in an Immunocompetent Individual Sana Yokoi, MD, PhD, Toshihiko Iizasa, MD, PhD, Kenzo.

Presentation transcript:

Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya Toyozaki, MD, Yukiko Haga, MD, Takehiko Fujisawa, MD, Hidemi Ohwada, MD The Annals of Thoracic Surgery Volume 73, Issue 6, Pages 1732-1735 (June 2002) DOI: 10.1016/S0003-4975(02)03504-X

Fig 1 Immunohistochemical staining of pulmonary adenocarcinoma of the lung with polyclonal antichromogranin A antibody. The tumor cells stain positive with antichromogranin A antibody (original magnification ×50). The Annals of Thoracic Surgery 2002 73, 1732-1735DOI: (10.1016/S0003-4975(02)03504-X)

Fig 2 The disease-free survival curve for pulmonary adenocarcinoma measuring 3.0 cm or less with T1 N0 M0 or T2 N0 M0. The disease-free survival for patients with NE-2 tumors is significantly lower than that those for patients with NE-0 and NE-1 tumors (p < 0.0005). NE-0 was defined as tumor negative for all neuroendocrine markers, NE-1 as tumor having 1% to 9% positive cells with at least one neuroendocrine marker, and NE-2 as tumor having 10% or more positive cells with at least one neuroendocrine marker. (NE = neuroendocrine.) The Annals of Thoracic Surgery 2002 73, 1732-1735DOI: (10.1016/S0003-4975(02)03504-X)